Eleven years after its founding, Boston BioLife is scaling its core mission of bridging emerging science and clinical medicine by co-presenting the Translational Longevity Summit, scheduled for October 7-11, 2026, at Harvard's Enterprise Research Campus in Boston. The event, organized with the Healthspan Action Coalition as part of Boston Longevity Week, represents a significant expansion of the organization's educational efforts into the rapidly evolving field of longevity medicine.
The summit's importance lies in its ambitious scope: it will convene leaders from science, medicine, technology, patient advocacy, policy, and investment to address how promising discoveries can be responsibly evaluated, translated, and advanced toward clinical application. This cross-sector approach is critical because the path from laboratory breakthrough to patient treatment is fraught with challenges, including regulatory hurdles, funding gaps, and the need for robust clinical validation. By bringing together diverse stakeholders, the summit aims to create a collaborative framework that can accelerate the translation of longevity research while maintaining rigorous safety and efficacy standards.
Founder Joseph P. Krieger views the summit as a pivotal milestone for Boston BioLife, which he established in July 2015. "When I founded Boston BioLife, the goal was to help physicians understand emerging science and determine how it could responsibly contribute to better patient care," Krieger said. "Eleven years later, this summit gives us the opportunity to expand that conversation across the entire translational ecosystem—from researchers and clinicians to patients, policymakers and investors."
Krieger's background in biochemistry and medical-device technology shaped the organization's focus on education that goes beyond simple device introduction. He recognized that successful clinical adoption requires understanding the underlying science, appropriate applications, limitations, regulatory considerations, and patient-safety implications. This philosophy has guided Boston BioLife's programming, which emphasizes accurate research and regulatory awareness. The Translational Longevity Summit will extend this work by exploring aging, healthspan, regenerative medicine, personalized care, and the practical challenges of moving discoveries from research environments into responsible real-world use.
A key differentiator of the summit is its emphasis on patient participation. People living with illness and age-related conditions bring essential perspectives on urgency, daily function, treatment burden, and unmet needs. Their involvement can help ensure that research, education, and innovation remain connected to the people medical progress is intended to serve. "Translation does not happen within a single laboratory, company or medical practice," Krieger added. "It requires researchers, clinicians, patients, regulators, advocates and responsible industry partners to ask better questions together. That is the community we are bringing together in Boston."
The choice of Harvard's Enterprise Research Campus for the summit holds particular significance for Krieger, a Massachusetts native who built his career near Boston's medical, academic, and scientific institutions. The location embodies the collaborative environment needed to advance translational medicine. As longevity science attracts increasing attention and investment, the summit's outcomes could influence how the field prioritizes research, shapes policy, and ultimately delivers therapies that improve healthspan. For more information about the event, visit the Translational Longevity Summit website. To learn about Boston BioLife's educational programs, visit Boston BioLife.
